Showing results (11-20 of 57) with videos related to

Sort By:
Pageof 6
Cancer Research|April 2, 2017
<i>ATM</i> Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung AdenocarcinomaAnna Schmitt, Gero Knittel, Daniela Welcker, et al.
Nature Communications|September 18, 2020
mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerabilityNiklas Gremke, Pierfrancesco Polo, Aaron Dort, et al.
Journal of Medical Internet Research|February 15, 2023
A New Option for Pain Prevention Using a Therapeutic Virtual Reality Solution for Bone Marrow Biopsy (REVEH Trial): Open-Label, Randomized, Multicenter, Phase 3 StudyKatell Le Du, Anne-Lise Septans, Frédéric Maloisel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 6, 2010
Methotrexate Reduces the Incidence of Severe Acute Graft-versus-Host Disease without Increasing the Risk of Relapse after Reduced-Intensity Allogeneic Stem Cell Transplantation from Unrelated DonorsStéphane Vigouroux, Reza Tabrizi, Cyril Melot, et al.
Experimental Hematology|May 26, 2018
Long-term follow-up of de novo chronic phase chronic myelogenous leukemia patients on front-line imatinibFranck Emmanuel Nicolini, Vincent Alcazer, Pascale Cony-Makhoul, et al.
Cancer Research|August 14, 2019
Dual Inhibition of GLUT1 and the ATR/CHK1 Kinase Axis Displays Synergistic Cytotoxicity in <i>KRAS</i>-Mutant Cancer CellsJohanna Erber, Joachim D Steiner, Jörg Isensee, et al.
American Journal of Hematology|October 9, 2014
ELN 2013 response status criteria: relevance for de novo imatinib chronic phase chronic myeloid leukemia patients?Gabriel Etienne, Stéphanie Dulucq, Axelle Lascaux, et al.
Scientific Reports|November 16, 2017
Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancerFabian Doerr, Julie George, Anna Schmitt, et al.
Pageof 6